WO2001052856A3 - Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives comme agents hydratants a action directe - Google Patents

Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives comme agents hydratants a action directe Download PDF

Info

Publication number
WO2001052856A3
WO2001052856A3 PCT/FR2001/000138 FR0100138W WO0152856A3 WO 2001052856 A3 WO2001052856 A3 WO 2001052856A3 FR 0100138 W FR0100138 W FR 0100138W WO 0152856 A3 WO0152856 A3 WO 0152856A3
Authority
WO
WIPO (PCT)
Prior art keywords
precursors
derivatives
dehydroepiandrosterone
oral administration
direct action
Prior art date
Application number
PCT/FR2001/000138
Other languages
English (en)
Other versions
WO2001052856A2 (fr
Inventor
La Charriere Olivier De
Stephanie Nouveau
Francoise Forette
Etienne-Emile Baulieu
Original Assignee
Assist Publ Hopitaux De Paris
Charriere Olivier De
Stephanie Nouveau
Francoise Forette
Baulieu Etienne Emile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris, Charriere Olivier De, Stephanie Nouveau, Francoise Forette, Baulieu Etienne Emile filed Critical Assist Publ Hopitaux De Paris
Priority to EP01907605A priority Critical patent/EP1248627A2/fr
Priority to AU2001235528A priority patent/AU2001235528A1/en
Priority to JP2001552903A priority patent/JP2003520238A/ja
Publication of WO2001052856A2 publication Critical patent/WO2001052856A2/fr
Publication of WO2001052856A3 publication Critical patent/WO2001052856A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Utilisation d'au moins un composé choisi dans le groupe constitué par la déhydroépiandrostérone, ses précurseurs chimiques, ses dérivés chimiques, ses précurseurs biologiques et ses dérivés métaboliques, pour la préparation d'une composition adaptée à l'administration par voie orale et destinée à être utilisée pour augmenter directement la teneur en eau de la peau.
PCT/FR2001/000138 2000-01-17 2001-01-17 Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives comme agents hydratants a action directe WO2001052856A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01907605A EP1248627A2 (fr) 2000-01-17 2001-01-17 Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives comme agents hydratants a action directe
AU2001235528A AU2001235528A1 (en) 2000-01-17 2001-01-17 Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action
JP2001552903A JP2003520238A (ja) 2000-01-17 2001-01-17 直接作用を有する水和剤としての、経口投与による、デヒドロエピアンドロステロン、その前駆体および誘導体の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/00551 2000-01-17
FR0000551A FR2803751B1 (fr) 2000-01-17 2000-01-17 Utilisation par voie orale de la dehydroepiandrosterone,de ses precurseurs et de ses derives comme agents hydratants a action directe

Publications (2)

Publication Number Publication Date
WO2001052856A2 WO2001052856A2 (fr) 2001-07-26
WO2001052856A3 true WO2001052856A3 (fr) 2002-06-06

Family

ID=8845991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000138 WO2001052856A2 (fr) 2000-01-17 2001-01-17 Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives comme agents hydratants a action directe

Country Status (6)

Country Link
US (1) US20030050293A1 (fr)
EP (1) EP1248627A2 (fr)
JP (1) JP2003520238A (fr)
AU (1) AU2001235528A1 (fr)
FR (1) FR2803751B1 (fr)
WO (1) WO2001052856A2 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3326901A (en) * 1965-04-16 1967-06-20 Irwin I Lubowe Pregnenolone salts of allantoin
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
EP0319638A1 (fr) * 1987-12-08 1989-06-14 Estee Lauder Inc. Compositions cosmétiques et pharmaceutiques contenant des liposomes et procédés pour l'utilisation de telles compositions
US5215759A (en) * 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
JPH07196467A (ja) * 1993-12-28 1995-08-01 Kanebo Ltd 表皮角質化促進剤
WO1997010255A1 (fr) * 1995-09-12 1997-03-20 Estee Lauder, Inc. Utilisation de nouveaux esters steroides agissant contre les affections de la peau
EP0908183A1 (fr) * 1997-10-08 1999-04-14 Institute For Advanced Skin Research Inc. Déhydroépiandrostérone ou ses dérivés pour augmenter la quantité d'acide hyaluronique dans la peau
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
FR2803519A1 (fr) * 2000-01-12 2001-07-13 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives pour ameliorer l'aspect papyrace de la peau

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3326901A (en) * 1965-04-16 1967-06-20 Irwin I Lubowe Pregnenolone salts of allantoin
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
EP0319638A1 (fr) * 1987-12-08 1989-06-14 Estee Lauder Inc. Compositions cosmétiques et pharmaceutiques contenant des liposomes et procédés pour l'utilisation de telles compositions
US5215759A (en) * 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
JPH07196467A (ja) * 1993-12-28 1995-08-01 Kanebo Ltd 表皮角質化促進剤
WO1997010255A1 (fr) * 1995-09-12 1997-03-20 Estee Lauder, Inc. Utilisation de nouveaux esters steroides agissant contre les affections de la peau
EP0908183A1 (fr) * 1997-10-08 1999-04-14 Institute For Advanced Skin Research Inc. Déhydroépiandrostérone ou ses dérivés pour augmenter la quantité d'acide hyaluronique dans la peau
FR2803519A1 (fr) * 2000-01-12 2001-07-13 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives pour ameliorer l'aspect papyrace de la peau

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002154272 *
E -E BAULIEU ET AL: "Dehydroepiandrosterone (DHEA), DHEA sulfate and aging: Contribution of the DHEAge study to a sociobiomedical issue", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 97, no. 8, 11 April 2000 (2000-04-11), pages 4279 - 4284, XP002141516, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
FR2803751B1 (fr) 2004-03-12
FR2803751A1 (fr) 2001-07-20
EP1248627A2 (fr) 2002-10-16
US20030050293A1 (en) 2003-03-13
AU2001235528A1 (en) 2001-07-31
WO2001052856A2 (fr) 2001-07-26
JP2003520238A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
WO2002056861A3 (fr) Compositions de mousse deformable syntactique et procedes de fabrication de celles-ci
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
WO2002019981A3 (fr) Compositions cosmetiques et pharmaceutiques et leur utilisation
EP1676488A3 (fr) Compositions et procédés de régulation du poids corporel
HK1047225A1 (en) Skin cleansing composition with improved stability.
MXPA01009951A (es) Composicion para aumentar permeacion de agentes topicos de la piel.
CA2429639A1 (fr) Monohydrate d'azithromycine stable
MY118345A (en) Repinotan kit
WO2002030467A3 (fr) Composition destinee a soigner des plaies, renfermant un compose actif du point de vue therapeutique, du miel notamment
EP2017269A9 (fr) Composition pharmaceutique comprenant forme cristalline II de Ritonavir et procédé de sa préparation
AU2001284135A1 (en) Use of tyramine in cosmetic compositions to lighten the skin
BRPI0406832A (pt) Método de reduzir o crescimento de pêlos em um ser humano, uso de um conjugado de alfa-difluorometilornitina ou um sal farmaceuticamente aceitável do mesmo, composto, composição, e, uso de um composto
AU2001281880A1 (en) Use of a formulation made of or containing at least one dissimilated milk serum
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1570842A3 (fr) Composition de chondroitin sulphate
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
NZ523606A (en) Pharmaceutical compositions and methods for use
WO2001052856A3 (fr) Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives comme agents hydratants a action directe
CA2366623A1 (fr) Composition de resorcinol
HK1073228A1 (en) Aromatic herb preparation
WO2005056066A3 (fr) Compositions medicinales dependant du ph
AU2003269871A1 (en) Radiosensitizer composition containing n-acetylphytosphingosine analogs and n,n-dimethyl-phytosphingosine analogs as the active ingredients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 552903

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001907605

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10181002

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001907605

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001907605

Country of ref document: EP